Premium
Minimal residual disease detected prior to hematopoietic cell transplantation
Author(s) -
Foster Jennifer H.,
Hawkins Douglas S.,
Loken Michael R.,
Wells Denise A.,
Thomson Blythe
Publication year - 2011
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.23079
Subject(s) - minimal residual disease , medicine , hematopoietic stem cell transplantation , blood cancer , disease , flow cytometry , transplantation , hematopoietic cell , lymphoblastic leukemia , leukemia , oncology , haematopoiesis , residual , cancer , pathology , immunology , stem cell , biology , genetics , algorithm , computer science
Previous studies to evaluate minimal disease in acute lymphoblastic leukemia (ALL) after treatment have relied on the diagnostic specimen to develop patient‐specific analytical probes. The diagnostic specimen is often not available in a tertiary setting; therefore, we evaluated the use of flow cytometry (FCM) using a “difference from normal” approach to detect residual disease prior to myeloablative allogeneic hematopoietic cell transplantation (HCT). Among 116 pediatric patients with ALL who were in morphological remission at time of transplant, we found that those patients who had detectable residual disease by FCM prior to HCT experienced significantly inferior outcome. Pediatr Blood Cancer 2011;57:163–165. © 2011 Wiley‐Liss, Inc.